We therefore tested the PR- and MAPK-dependent regulation of selected genes co-associated with ERBB2 overexpression (Figure 5A) and SUMO-sensitivity (above) in HER2-amplified but SR-positive BT-474 breast cancer cells that contain constitutively activated MAPKs [69]. The gene discussed is ERBB2; the disease is breast cancer.